Type 1 Diabetes: Low-Dose Interleukin-2 Study

We are studying the effects of low-dose interleukin-2 on patients with type 1 diabetes who still have some insulin production. The aim is to see if this treatment can help improve their immune response and insulin levels.

16-20 visitsEfficacy phase (II)Investigational MedicinesOralInjectionEndocrinologyInternal Medicine

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Aldesleukin
Aldesleukin is a synthetic form of a natural immune-signaling protein that boosts the body's immune response to help treat certain cancers.
Ciclosporin
Ciclosporin is a substance that suppresses the immune system to prevent organ transplant rejection and treat autoimmune conditions.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Ilt-101

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Assistance Publique Hopitaux De Paris
Service de Diabétologie
Maison Blanche, France
Assistance Publique Hopitaux De Paris
Service de Diabétologie
Salpêtrière, France
Assistance Publique Hopitaux De Paris
CIC Pitié-Salpêtrière
Salpêtrière, France
Sponsor: Assistance Publique Hopitaux De Paris
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.